# Daily Report — Tuesday, 2026-09-08 — **BOTH BOOKS**

*Agentic account (••••7339, `limited_margin` / `option_level_3`). Written at 14:20 CT / 19:20 UTC by the first run at or after the 14:15 CT report window — on time and in-session, ~40 minutes before the bell. All quotes stamped 19:20Z. Prompt v10.*

**Headline: no trade in either book, for the twenty-seventh consecutive run today. The equity book is fully occupied (4 of the 3-4 target swings) and every position is red, which structurally disables the only profit-taking exit it has. The day's story is a macro repricing that hit what we own.**

---

## 1. Positions — what we own and why

### Equity swing book — 4 open (target 3-4, hard band 3-5)

| Name | Shares | Entry | Live 19:20Z | Cost | Value | P/L | Held | **Time stop** |
|---|---|---|---|---|---|---|---|---|
| LLY | 0.420254 | 1189.7553 | 1123.4118 | $500.00 | $472.12 | **−$27.88 (−5.58%)** | 12d | **2026-09-10 (2d)** |
| MDLZ | 7.988509 | 62.5899 | 61.6450 | $500.00 | $492.45 | −$7.55 (−1.51%) | 11d | **2026-09-11 (3d)** |
| MMM | 2.884552 | 173.3371 | 167.3000 | $500.00 | $482.59 | −$17.41 (−3.48%) | 8d | 2026-09-14 (6d) |
| GD | 1.335314 | 374.4437 | 357.1350 | $500.00 | $476.89 | −$23.11 (−4.62%) | 7d | 2026-09-15 (7d) |
| | | | | **$2,000.00** | **$1,924.04** | **−$75.96 (−3.80%)** | | |

**Why we own each one** — all four are Connors RSI(2) mean-reversion swings: bought oversold (RSI2 < 10) inside a rising 200-day uptrend, intended 1-3 week holds.
- **LLY** — pharma; thesis researched and confirmed **INTACT** at 15:45Z today (logged as `_LLY_THESIS_RESEARCHED_INTACT_2026-09-08T15-45Z`). It is down because the *sector* was repriced today, not because the company's story changed.
- **MDLZ** — packaged food, low-beta defensive. The only name bid today (+0.60% on the session).
- **MMM** — industrial conglomerate.
- **GD** — defense prime.

### Options book — 1 open (the authorized hedge)

| Contract | Qty | Cost basis | Mark 19:20Z | P/L | DTE |
|---|---|---|---|---|---|
| SPY 2026-11-20 **700P** | 1 | $749.00 | $489.00 (4.89 mid, 4.88 × 4.90) | **−$260.00 (−34.71%)** | 73 |

**Why we own it:** it is Ryan's authorized defensive put hedge — insurance, not a directional trade. It is **exempt from every premium backstop** (a hedge is *expected* to decay while the market holds up) and is held to a roll/close decision with Ryan at ~21 DTE. Greeks now: delta −0.132, theta −$9.25/day, IV 20.6%, OI 31,770. It is deep out-of-the-money with SPY at 766.70 against a 700 strike — that is what a −35% mark on insurance looks like when the insured event has not happened.

---

## 2. Actions taken today — **NONE**

No orders were placed in either book. Broker-confirmed, not assumed: `get_equity_orders` and `get_option_orders` for 2026-09-08 both return **empty**.

**Realized P/L today: $0.00** in both books. Options realized $0.00 against the −$400 daily cap. **Entry throttles: 0 of 8 options used, 0 of 3 equities used.**

---

## 3. Actions CONSIDERED and skipped — the educational section

### 3a. Equity entry — the 16-name RSI2 cohort. **Graded B. Declined.**

Today's screen produced an unusually large oversold cohort: SBUX (RSI2 2.5), PATH (2.9), AMGN (3.1), WBD (4.4), ABBV (4.9), CL (5.2), MA (5.9), ABNB (6.7), VRTX (6.9), DLTR (7.1), BMY (7.2), PFE (8.6), V (9.0), plus the three we already hold. Sixteen names is a lot of signal. It was still declined, on four independent grounds — and the *first* one is the one that matters most:

1. **This is not sixteen ideas. It is one idea printed sixteen times.** Nearly every name on that list is a defensive or rate-sensitive large cap — pharma (AMGN, ABBV, BMY, PFE, VRTX), staples (CL, SBUX, DLTR), payments (MA, V). They are oversold *together*, for the *same reason*, on the *same day*. Buying one is a bet on a macro reversal; buying one and calling it diversification is worse, because we would be adding a fifth correlated position to a book of four already-correlated ones. A cohort that oversells as a bloc is a **B-grade** setup no matter how clean each individual RSI2 print looks.
2. **The screen is measuring the cause, not an opportunity.** RSI(2) is purely technical and knows nothing about *why* a name is oversold. Today's driver is a live, unresolved macro repricing (see §5). A mean-reversion entry into the *first session* of a repricing is buying the knife before the catalyst that dropped it — the catalyst is still two days out.
3. **The slot arithmetic makes a fifth entry expensive, not cheap.** Under the concentration policy the book already holds 4 of its 3-4 target swings. A fifth would size against deployable capital and run to the **30% per-name cap = $1,161.78** — a position larger than any we hold, in the weakest-graded cohort of the week. Concentration is authorized for **A/A+ only**; the policy is explicit that a B-grade gets *no* position rather than a small one, precisely so that "fewer positions" means *more selective* and not merely *bigger*.
4. **The sequencing is backwards.** Two time stops fire this week — **LLY on 09-10 and MDLZ on 09-11** — mechanically returning roughly $960 of capital. Spending $1,161 today to be handed $960 back in 48 hours, across a CPI print, is poor capital sequencing even if the name were good.

**A `_cash_hold` record governs this and it is deliberately self-destructing.** Opportunity: re-grade this cohort once the macro repricing resolves. Trigger: **PPI Thu 2026-09-10, CPI Fri 2026-09-11 08:30 ET**. Expiry: **2026-09-14** — on that date the hold dissolves automatically and capital returns to full deployment whether or not a better setup has appeared. This is not a cash floor; there is no percentage cash target anywhere in this system. If an A-grade setup clears the bar tomorrow it is taken in full and the hold is void on the spot.

### 3b. Options TACTICAL scalp. **No trigger. Declined.**

The tape produced a genuinely dramatic moment today and it still did not produce a trade — which is the whole point of having a price clause.

At **18:45Z a record-participation flush hit both indices**: SPY traded 415,484 shares in one 5-minute bucket (**463% of its trailing baseline**), QQQ 207,543 (**426%**). Both buckets reconciled *exactly* against their 1-minute sums, so this was real flow and not a feed artifact. **And the levels held anyway.** SPY wicked to 765.67 and closed the bucket back above; as of 19:20Z it sits at 766.70, **1.03 above its session low**. QQQ bottomed 717.91 and now sits 718.86, **0.95 above its own**. A TACTICAL entry requires a level actually *breaking*, and neither broke.

**Index agreement also fails**, which is an independent veto: SPY is **−0.45% and below its 20-day** while QQQ is **−0.01% and above its own 20-day**. The two indices are telling different stories, so there is no confirmed direction to trade.

Two further bars, either of which alone would be decisive: we are **inside the closing window**, where the volume-confirmation denominator becomes unreadable as auction flow contaminates it — so a fire here could not be confirmed even if price cooperated. And a TACTICAL entry now carries **overnight**, where the median gap exceeds the track's own −30% stop distance in underlying terms; that converts a stop-managed scalp into an unmanaged coin flip.

*Worth recording honestly:* checked for the closing-flow step-up at 19:20Z and **it has not appeared yet** — SPY's last four buckets (113,717 / 69,839 / 110,647 / 95,059) are running at or slightly *below* the pre-flush prevailing rate of ~97,000. This is the second session that has failed to reproduce the "40-minute" closing boundary measured on 2026-08-28, which is exactly what that finding instructed: **detect the boundary per session, never adopt it as a constant.**

### 3c. Options CORE swing. **No candidate.**

Nothing on the report's options lists cleared the CORE stack. The bullish momentum names (LITE, MU, AAOI, BE, AEHR) are extended small/mid-caps whose chains do not survive the ≤10%-of-mid liquidity gate at this account size — a repeatedly measured result, not an assumption. The bearish list (BYND, FIG, INTU, ZTS, COIN) offers no entry the trend-maturity gate would clear: these are names already deep into a decline, which is late-stage by default and needs a reason the move will *continue*, not evidence it already happened.

---

## 4. Sleeve state

| | |
|---|---|
| **Total account value** | **$3,872.59** |
| Equity value | $1,924.41 |
| Options value | $489.00 |
| Cash | $1,459.18 |
| `unleveraged_buying_power` | **$1,459.18** — equal to cash and to `buying_power`, so **no margin is being extended** |
| Operational reserve (5% of total, recomputed) | $193.63 |
| **Deployable capital** | **$1,265.55** |
| Per-name cap (30% of account) | $1,161.78 |
| Premium at risk — options | $749.00 cost basis, all of it the exempt hedge. **$0 in TACTICAL, $0 in CORE.** |
| Realized options P/L today | **$0.00** vs the −$400 cap |
| Entry throttles | **0 of 8** options, **0 of 3** equities |
| Open equity slots | **4 of the 3-4 target** (band 3-5) |
| Open options slots | 0 of 5 (hedge excluded) |

Deployable **exceeds** the $600 minimum entry comfortably, so the **rotation gate is dormant** — a new idea does not have to beat an existing position to get funded; there is cash for it. The bar today was quality, not capital.

**Reconciliation: ZERO DRIFT, both books, broker read first.** 4 equity positions matched on quantity *and* average cost; 1 option position (qty 1.0000 @ $749.00, all `pending_*` zero). No sibling-run fill across twenty-seven runs.

---

## 5. What actually happened today — the tape

The regime was **relabelled at 17:25Z from "healthcare rout" to "RATE SHOCK"**, and that relabel is the most useful thing in this report.

| | Session change |
|---|---|
| SPY | **−0.453%** (766.70, below its 20-day at 769.05) |
| QQQ | **−0.014%** (718.86, above its 20-day at 717.51) |
| XLV (healthcare) | **−2.267%** |
| XLF (financials) | **−1.145%** |
| XLK (tech) | **+0.416%** |
| XLE (energy) | **+1.319%** |

**Why the relabel matters.** The first read this morning was that healthcare was having an idiosyncratic bad day — XLV was a 3× outlier against the next-worst sector, and there was a real single-name driver (a Phase 3 miss on pelacarsen, which read across the pharma complex). That explanation is true but **incomplete**, and treating it as the whole story would have been the error. Financials down 1.1%, energy up 1.3%, and tech *green* while the broad index is red is not a healthcare story — that is the signature of a **rate/duration repricing**, where long-duration defensives and rate-sensitive financials get sold together and the cyclical/commodity end catches a bid.

That distinction changes the trade. If it were a healthcare rout, the oversold pharma names on today's screen would be a clean contrarian setup. Because it is a rate repricing with **PPI Thursday and CPI Friday still ahead**, those same names are a leveraged bet on an unresolved macro print — and the entry gates correctly refuse it.

This is also why LLY being down 5.58% is not read as a broken thesis: the position was researched to **intact** today, and the price action is the sector's, not the company's.

---

## 6. Tomorrow's watchpoints

1. **LLY time stop fires 2026-09-10 (Thursday).** Held 12 of 14 days. It will be **sold green or red** — currently red at −$27.88. This is the book's only mechanical loss discipline and it is not discretionary. Within 3 days of a time stop, a bounce is worth selling *into* rather than out of, so if LLY prints strength Wednesday that is the preferred exit window.
2. **MDLZ time stop fires 2026-09-11 (Friday).** Held 11 of 14 days, −$7.55 — the closest to flat of the four and the most likely to exit near breakeven.
3. **These two land inside a four-day cluster with MMM (09-14) and GD (09-15).** All four swings expire within one four-day window, so the book mechanically liquidates to near-cash next week regardless of price. That is a known structural feature of having entered four positions in one five-session stretch — worth planning re-entry around, not reacting to.
4. **PPI Thursday 09-10, CPI Friday 09-11 08:30 ET** (headline seen 3.4%, core 2.4%). This is the catalyst the cash hold names. It resolves inside the same window the two time stops fire — so roughly $960 of capital returns *just as* the macro uncertainty clears. That is favourable sequencing and is a large part of why waiting costs little.
5. **The `_cash_hold` expires 2026-09-14** whatever CPI does. No run may extend it without a new named catalyst and a new expiry.
6. **The SPY 700P hedge reaches its ~21-DTE review around 2026-10-30.** No action needed now at 73 DTE; it stays exempt from premium backstops.
7. **Watch whether the RSI2 cohort survives the print.** If CPI resolves benignly and the defensive complex stabilises, that 16-name list re-grades from "one correlated macro bet" to a genuine menu — and the book will have capital to act on it. If it resolves badly, the same list keeps falling and declining today will have been the entire point.

---

## 7. Governance notes

- **HARD RULE 9 intact.** No approval is claimed, quoted, or implied anywhere in this run. No violation flag was cleared. The `_cash_hold` was recorded by an automation run and says so explicitly.
- **No stops placed, ever** (HARD RULE 5). None of the four positions carries a price stop; none is "green enough" (needs entry ÷ 0.85) to trigger a SET TRAILING STOP alert for Ryan.
- **Weekly calibration ran pre-open at 10:25Z: NO CHANGE on both books.** The in-regime gate blocked all tuning — the parameters being evaluated are newer than the trades available to evaluate them, so there is no legitimate sample yet. That is the guard working, not a failure.
- **No margin.** `unleveraged_buying_power` equals `buying_power` equals cash; total deployment is bounded by the smaller of the two by construction.

---

*Both books flat by choice, not by constraint. There was $1,265.55 of deployable capital available all day and sixteen technically-valid oversold signals on the screen; the reason nothing was bought is that they were all the same signal, two days ahead of the event that will decide it.*
